Luo S[au] - Search Results

Year	Number of Results
1963	1
1979	1
1980	13
1981	2
1982	6
1983	3
1984	1
1985	7
1986	4
1987	13
1988	13
1989	15
1990	12
1991	13
1992	17
1993	16
1994	22
1995	23
1996	14
1997	26
1998	28
1999	31
2000	47
2001	43
2002	46
2003	66
2004	82
2005	121
2006	113
2007	119
2008	144
2009	145
2010	220
2011	201
2012	239
2013	311
2014	372
2015	425
2016	424
2017	520
2018	553
2019	767
2020	891
2021	553

1

Regulation of PD-L1 expression in the tumor microenvironment.

Yi M, Niu M, Xu L, Luo S, Wu K. Yi M, et al. Among authors: luo s. J Hematol Oncol. 2021 Jan 7;14(1):10. doi: 10.1186/s13045-020-01027-5. J Hematol Oncol. 2021. PMID: 33413496 Free PMC article. Review.

2

Exosome-mediated delivery of antisense oligonucleotides targeting α-synuclein ameliorates the pathology in a mouse model of Parkinson's disease.

Yang J, Luo S, Zhang J, Yu T, Fu Z, Zheng Y, Xu X, Liu C, Fan M, Zhang Z. Yang J, et al. Among authors: luo s. Neurobiol Dis. 2021 Jan;148:105218. doi: 10.1016/j.nbd.2020.105218. Epub 2020 Dec 6. Neurobiol Dis. 2021. PMID: 33296726 Free article.

3

Clinical practice guidelines for the management of liver metastases from extrahepatic primary cancers 2021.

Yamamoto M, Yoshida M, Furuse J, Sano K, Ohtsuka M, Yamashita S, Beppu T, Iwashita Y, Wada K, Nakajima TE, Sakamoto K, Hayano K, Mori Y, Asai K, Matsuyama R, Hirashita T, Hibi T, Sakai N, Tabata T, Kawakami H, Takeda H, Mizukami T, Ozaka M, Ueno M, Naito Y, Okano N, Ueno T, Hijioka S, Shikata S, Ukai T, Strasberg S, Sarr MG, Jagannath P, Hwang TL, Han HS, Yoon YS, Wang HJ, Luo SC, Adam R, Gimenez M, Scatton O, Oh DY, Takada T. Yamamoto M, et al. Among authors: luo sc. J Hepatobiliary Pancreat Sci. 2021 Jan;28(1):1-25. doi: 10.1002/jhbp.868. Epub 2020 Dec 12. J Hepatobiliary Pancreat Sci. 2021. PMID: 33200538

4

Improvement of obesity-associated disorders by a small-molecule drug targeting mitochondria of adipose tissue macrophages.

Wang Y, Tang B, Long L, Luo P, Xiang W, Li X, Wang H, Jiang Q, Tan X, Luo S, Li H, Wang Z, Chen Z, Leng Y, Jiang Z, Wang Y, Ma L, Wang R, Zeng C, Liu Z, Wang Y, Miao H, Shi C. Wang Y, et al. Among authors: luo s. Nat Commun. 2021 Jan 4;12(1):102. doi: 10.1038/s41467-020-20315-9. Nat Commun. 2021. PMID: 33397994 Free PMC article.

5

Growth hormone activates PI3K/Akt signaling and inhibits ROS accumulation and apoptosis in granulosa cells of patients with polycystic ovary syndrome.

Gong Y, Luo S, Fan P, Zhu H, Li Y, Huang W. Gong Y, et al. Among authors: luo s. Reprod Biol Endocrinol. 2020 Dec 7;18(1):121. doi: 10.1186/s12958-020-00677-x. Reprod Biol Endocrinol. 2020. PMID: 33287836 Free PMC article.

6

Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.

Liu C, Liu R, Wang B, Lian J, Yao Y, Sun H, Zhang C, Fang L, Guan X, Shi J, Han S, Zhan F, Luo S, Yao Y, Zheng T, Zhang Y. Liu C, et al. Among authors: luo s. J Immunother Cancer. 2021 Jan;9(1):e001895. doi: 10.1136/jitc-2020-001895. J Immunother Cancer. 2021. PMID: 33462141 Free PMC article.

7

Modified FOLFOXIRI With or Without Cetuximab as Conversion Therapy in Patients with RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer: The FOCULM Multicenter Phase II Trial.

Hu H, Wang K, Huang M, Kang L, Wang W, Wang H, Qiu M, Lin R, Zhang H, Lan P, Wu X, Liu G, Wan Y, Liu M, Zhou Z, Huang Y, Li F, Zhang J, Cai Y, Ma T, Zhou J, Wang H, Ling J, Cai Y, Wu Z, Luo S, Ling L, Deng Y. Hu H, et al. Among authors: luo s. Oncologist. 2021 Jan;26(1):e90-e98. doi: 10.1634/theoncologist.2020-0563. Epub 2020 Sep 3. Oncologist. 2021. PMID: 33400355 Free PMC article. Clinical Trial.

8

From Rheumatoid Factor to Anti-Citrullinated Protein Antibodies and Anti-Carbamylated Protein Antibodies for Diagnosis and Prognosis Prediction in Patients with Rheumatoid Arthritis.

Wu CY, Yang HY, Luo SF, Lai JH. Wu CY, et al. Among authors: luo sf. Int J Mol Sci. 2021 Jan 12;22(2):686. doi: 10.3390/ijms22020686. Int J Mol Sci. 2021. PMID: 33445768 Free PMC article. Review.

9

New possible silver lining for pancreatic cancer therapy: Hydrogen sulfide and its donors.

Hu X, Xiao Y, Sun J, Ji B, Luo S, Wu B, Zheng C, Wang P, Xu F, Cheng K, Hua H, Li D. Hu X, et al. Among authors: luo s. Acta Pharm Sin B. 2021 May;11(5):1148-1157. doi: 10.1016/j.apsb.2020.10.019. Epub 2020 Oct 31. Acta Pharm Sin B. 2021. PMID: 34094825 Free PMC article. Review.

10

Immune signature-based risk stratification and prediction of immune checkpoint inhibitor's efficacy for lung adenocarcinoma.

Yi M, Li A, Zhou L, Chu Q, Luo S, Wu K. Yi M, et al. Among authors: luo s. Cancer Immunol Immunother. 2021 Jun;70(6):1705-1719. doi: 10.1007/s00262-020-02817-z. Epub 2021 Jan 2. Cancer Immunol Immunother. 2021. PMID: 33386920 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results